Overview

Phase II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Trastuzumab

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
To evaluate the pathologic complete response rate to preoperative administration of Paclitaxel, Gemcitabine, and Trastuzumab (HerceptinÒ) (PGH)
Phase:
Phase 2
Details
Lead Sponsor:
Jungsil Ro
Treatments:
Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel
Trastuzumab